Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) ...

Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

Imatinib mesylate, a protein tyrosine kinase inhibitor, can induce caspase-independent death of tumour cells, can enhance natural killer (NK)-cell activities and can induce the expansion of a ...

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded ...

We further discuss the current clinical landscape for the development of LSD1 inhibitors and where sarcomas have been included in early clinical trials. Once diagnosed, the standard of care for ...

对于肺癌的驱动基因来说，比较常见的是EGFR基因突变，EGFR属于HER家族的一个基因，在这个基因家族还有一个名为HER3的捣乱家伙，HER3过量表达在多种实体肿瘤被发现，包括乳腺癌、头颈癌、肺癌、结直肠癌、前列腺癌和卵巢癌。此外HER3基因过量表达 ...

Copy number variants (CNVs) arise by homologous recombination (HR) between repeated sequences (recurrent CNVs) or by non-homologous recombination mechanisms that occur throughout the genome (non ...